Venture Fund Member Profile
|
 |
 |
Radius Ventures is a venture capital firm focused on leading-edge health and life sciences companies. Formed in 1997, Radius searches for the winners of tomorrow - entrepreneurs whose ideas and talents qualify them to pursue large market opportunities successfully. We seek opportunities across a broad spectrum including biotechnology and pharmaceuticals, medical devices, services and healthcare/life sciences information technology. Our goal is to identify companies on the cusp of major value creation where we can envision liquidity over a three to five year time frame.
We invest much more than money in our companies. Our distinctive approach blends significant financial investment with unique access to world-class intellectual capital. Our goal is to fuel the rapid growth of our portfolio companies and drive substantial value creation. As collaborative partners, we pledge our full support throughout the ups and downs of a company's growth.
Radius helps entrepreneurs accelerate their business development, compress timelines to critical milestones, build high-caliber management teams, and reach a higher valuation plateau for their next round of financing or exit. Because we invest early in a company's development, we can make a substantial difference in its trajectory of growth, risk profile and pace of value creation. At Radius, the most rewarding and satisfying part of our work is seeing each of our portfolio companies succeed to its fullest potential.
Radius currently manages three funds with total committed capital of approximately $200 million. Generally, we invest up to $10 million over initial and subsequent financing rounds, as a lead or syndicate investor.
 |
Jordan Davis
Founder and Managing Partner
Radius Ventures |
Jordan S. Davis is a Founder and Managing Partner of Radius Ventures, which acts as the Investment Advisor to the Radius Funds. Prior to Radius, Jordan served as a Managing Director at KBL Healthcare, Inc., a health and life sciences venture capital and investment banking organization, and cofounded and served as Vice President and Director of KBL Healthcare Acquisition Corp., a publicly-traded Specified Purpose Acquisition Company (SPAC). Previously, Jordan was primarily engaged in financial advisory and money management having served for five years in the Private Client Services and International Equity divisions of Morgan Stanley & Co., Inc. He was a founder of Cambridge Heart, Inc., a cardiology device company, and Voxware, Inc., a speech technology company, both companies that achieved IPOs in 1996. Jordan currently serves on the board of directors of Health Language, Inc., is an Executive Board Advisor of Biostorage Technologies, Inc. and a board observer of NuGEN Technologies, Inc. and Zettacore, Inc., all Radius portfolio companies. He also serves on the board of directors HealthCorps, a charitable organization dedicated to educating and empowering youth to take charge of their health. Jordan earned an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Economics from The State University of New York at Binghamton.
Representative Investments
 |
ActiveHealth Management, Inc. was acquired by Aetna Inc. in May 2005. Prior to the acquisition, ActiveHealth Management was a healthcare information technology and services company focused on improving the effectiveness of disease diagnosis and management. Key to the company's capabilities was proprietary software that integrated a wide array of clinical information with protocols and standards to elevate the quality of care in real time and reduce the overall cost for payors.
|
 |
Comprehensive Neuroscience, Inc. provides a full range of clinical trials management services with a focus on neuro-psychiatric and other central nervous system disorders. The company also provides behavioral health care-management services to public/government and private healthcare organizations. |
 |
Medingo Ltd. is a medical device company developing next generation insulin dispensing and glucose monitoring technologies for patients with diabetes. Medingo's initial product, The Solo™, is one of the first products in a new category of insulin pumps called "dispensing patches" that will address the shortcomings of traditional larger "pager-like" pumps. |
 |
Targanta Therapeutics, Inc. is a biotechnology company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Targanta's lead drug candidate, Oritavancin, has completed two Phase III clinical trials in complicated skin and skin structure infections and is under study for additional indications and unique treatment regimens.
(www.targanta.com) |
Jordan participated in the FundingPost event: NYC Venture Capital and Angel Showcase
on Thursday, February 3, 2011 in NY, Sponsored by Credit Suisse, Ameritech Media
To list your Company on our website and make your profile available to Jordan and 7,500+ other VCs and Angel Investors, Click Here.
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
